ANGOAngioDynamics, Inc.
Price
+3.5%1YEnd-of-day closes, not the intraday tick.
The checks lean against it
Quality shaky, a flag to check, demanding price, growth steady, the market undecided.
Charts
As reported to the SEC, without any scoring.
AngioDynamics, Inc. (ANGO) reported revenue of $81M in Q1 2027 (quarter ended Aug 31, 2026), up 6.9% from the same quarter a year earlier. That came with a gross margin of 59% and net loss of $7.1M. For the full year FY2026, revenue was $320M (+9.5% year on year) and net income −$37M. The next results filing is expected around Jan 5, 2027, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 8, 2026AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability.Earnings release · press release
- Oct 8, 2026On October 3, 2026, AngioDynamics, Inc. (“AngioDynamics” or the “Company”) entered into an employment agreement with Eric Honroth (the “Employment Agreement”), pursuant to which Mr. Honroth will serve as President and Chief Executive Officer of the Company.Material agreement entered · Form 8-K
- Jul 14, 2026AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Medical Instruments & Supplies
Ranks #20 of 21 by RyuScore